Pancreatic Cancer Research

ResearcherEpworth HospitalActive in the last 2 years

Daniel Gerald Croagh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6430-6741; OpenAlex author ID A5078792014, A5137808344. Sources: OpenAlex.

Their work

Papers
42 (first author 2, last author 13)
Trials
0
Grants
0
Labs led
2
Collaborators
111
Papers, trials and grants by year

2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 5 papers · 2022: 6 papers · 2023: 5 papers · 2024: 5 papers · 2025: 5 papers · 2026: 8 papers

Papers 42

  1. GOT1 Inhibition Induces Extracellular Matrix Remodeling in Pancreatic Cancer. Co-author DOI 10.1002/advs.202516578↗
  2. Absolute risk of pancreatic cancer in people with acute pancreatitis - theAustralian experience. Co-author DOI 10.1016/j.hpb.2026.05.011↗
  3. Cancer cell-intrinsic inflammasome protein ASC links innate immunity with mitochondrial metabolism in driving pancreatic cancer. Co-author DOI 10.1038/s41467-026-69398-w↗
  4. Endoscopic ultrasound molecular evaluation of pancreatic cancer trial to profile molecular landscape of inoperable pancreatic ductal adenocarcinoma. Last author DOI 10.1055/a-2733-1068↗
  5. Prognostic value of KRAS gene mutations in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Last author DOI 10.1080/00365521.2025.2610630↗
  6. Factors Associated With Pancreatectomy Among Australians With Pancreatic Cancer: A Population-Based Study. Co-author DOI 10.1111/ans.70788↗
  7. Evidence Mapping of ctDNA Reporting in Pancreatic Ductal Adenocarcinoma: Toward a Shared Quantitative Language for ctDNA. Co-author DOI 10.3390/cancers18081318↗
  8. The sensitivity of decision support tools for identifying patients with pancreatic cancer: an observational study. Co-author DOI 10.3399/bjgpo.2025.0142↗
  9. Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: an international multicentre retrospectiv… Co-author DOI 10.1016/j.hpb.2024.11.015↗
  10. Aiming for high quality of care for completed resections and improved margin status in pancreatic cancer surgery. Co-author DOI 10.1016/j.pan.2025.09.029↗
  11. Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy, symptom control and optional supplemental jejunal … Last author DOI 10.1186/s12937-025-01113-9↗
  12. Case Report: Two cases of long-term survival in advanced pancreatic cancer patients following treatment with KRAS G12C inhibitors. Last author DOI 10.3389/fonc.2025.1691760↗
  13. Venous Resection During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma-A Multicentre Propensity Score Matching Analysis of the Recurrence After Whi… Co-author DOI 10.3390/cancers17071223↗
  14. Five-year recurrence/survival after pancreatoduodenectomy for pancreatic adenocarcinoma: does pre-existing diabetes matter? Results from the Recurrence After W… Co-author DOI 10.1016/j.hpb.2024.04.010↗
  15. Outcomes of phosphorus-32 microparticle intratumoral implantation added to chemotherapy in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.igie.2024.06.005↗
  16. Handgrip Strength Predicts Survival in Patients With Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002319↗
  17. Supplemental tube feeding: qualitative study of patient perspectives in advanced pancreatic cancer. Co-author DOI 10.1136/spcare-2024-004836↗
  18. Evaluation of Needles in Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreatic Cancer for Genetic Yield and Quality. Last author DOI 10.7759/cureus.68431↗
  19. Endoscopic Ultrasound-Guided Fine-Needle Biopsies to Generate Preclinical Disease Models to Study Inflammation in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1007/978-1-0716-3331-1_4↗
  20. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  21. Relationship between circulating tumour DNA and skeletal muscle stores at diagnosis of pancreatic ductal adenocarcinoma: a cross-sectional study. Last author DOI 10.1038/s41598-023-36643-x↗
  22. Circulating Tumor DNA Is an Accurate Diagnostic Tool and Strong Prognostic Marker in Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002239↗
  23. Does an extensive diagnostic workup for upfront resectable pancreatic cancer result in a delay which affects survival? Results from an international multicentr… Co-author DOI 10.14701/ahbps.23-042↗
  24. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRI… Co-author DOI 10.1016/j.esmoop.2021.100356↗
  25. The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2021.11.005↗
  26. Prognostic models to predict survival in patients with pancreatic cancer: a systematic review. Co-author DOI 10.1016/j.hpb.2022.01.011↗
  27. National clinical quality registry for pancreatic cancer - the time is nigh. Last author DOI 10.1111/ans.17747↗
  28. Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and L… Co-author DOI 10.1200/po.21.00437↗
  29. KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation? Last author DOI 10.3390/cells11193175↗
  30. A decision support tool for the detection of pancreatic cancer in general practice: A modified Delphi consensus. Co-author DOI 10.1016/j.pan.2021.08.007↗
  31. TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-021-01992-2↗
  32. Targeted Transcriptome and KRAS Mutation Analysis Improve the Diagnostic Performance of EUS-FNA Biopsies in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-21-1107↗
  33. EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy. Last author DOI 10.3389/fonc.2021.770022↗
  34. The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial. Co-author DOI 10.4103/eus-d-20-00230↗
  35. Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review. Co-author DOI 10.1016/j.hpb.2019.09.002↗
  36. Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework. Co-author DOI 10.1371/journal.pone.0243312↗
  37. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12123816↗
  38. Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. Co-author DOI 10.1016/j.hpb.2018.08.016↗
  39. Body Composition Adjusted Dosing of Gemcitabine-Nab-Paclitaxel in Pancreatic Cancer Does Not Predict Toxicity Compared to Body Surface Area Dosing. First author DOI 10.1080/01635581.2018.1542011↗
  40. Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer. Co-author DOI 10.3390/cancers10020035↗
  41. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors. Last author DOI 10.1002/ijc.30648↗
  42. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group … Co-author DOI 10.1080/14737140.2017.1369882↗

Closest collaborators

The 25 strongest of 111 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joanne Lundy · 15 shared papers, 2018–2026 · strength 2.82
  2. John Raymond Zalcberg · 13 shared papers, 2019–2026 · strength 2.05
  3. Brendan John Jenkins · 11 shared papers, 2017–2026 · strength 1.65
  4. Rachel Ε. Neale · 10 shared papers, 2019–2026 · strength 1.53
  5. Saeed Aslani · 3 shared papers, 2025–2026 · strength 1.35
  6. Charles H. C. Pilgrim · 8 shared papers, 2019–2025 · strength 0.99
  7. Liane Ioannou · 7 shared papers, 2019–2025 · strength 0.96
  8. Owen McKay · 3 shared papers, 2022–2026 · strength 0.79
  9. Henry Shen · 3 shared papers, 2022–2026 · strength 0.77
  10. Belinda Lee · 3 shared papers, 2021–2026 · strength 0.72
  11. Lauren Hanna · 3 shared papers, 2023–2025 · strength 0.70
  12. Ashika D. Maharaj · 6 shared papers, 2019–2025 · strength 0.70
  13. Neil Donald Merrett · 6 shared papers, 2019–2025 · strength 0.70
  14. Sue Evans · 6 shared papers, 2019–2025 · strength 0.70
  15. Kate White · 6 shared papers, 2019–2025 · strength 0.70
  16. James G. Kench · 5 shared papers, 2019–2025 · strength 0.61
  17. John Albert Windsor · 3 shared papers, 2021–2026 · strength 0.56
  18. Andrew J. Metz · 3 shared papers, 2021–2026 · strength 0.56
  19. Vinod Ganju · 2 shared papers, 2022–2025 · strength 0.55
  20. Marion Harris · 4 shared papers, 2021–2022 · strength 0.52
  21. Savio George Barreto · 2 shared papers, 2026 · strength 0.48
  22. Rav Sellahewa · 2 shared papers, 2023 · strength 0.48
  23. Kate Furness · 2 shared papers, 2024–2025 · strength 0.46
  24. Mary A. Waterhouse · 2 shared papers, 2026 · strength 0.45
  25. David Goldstein · 3 shared papers, 2022–2025 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.